Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes

Samantha Roberts,1 Eleanor Barry,1 Dawn Craig,2 Mara Airoldi,3 Gwyn Bevan,3 Trisha Greenhalgh1

ABSTRACT

Objective Explore the cost-effectiveness of lifestyle interventions and metformin in reducing subsequent incidence of type 2 diabetes, both alone and in combination with a screening programme to identify high-risk individuals.

Design Systematic review of economic evaluations.

Data sources and eligibility criteria Database searches (Embase, Medline, PreMedline, NHS EED) and citation tracking identified economic evaluations of lifestyle interventions or metformin alone or in combination with screening programmes in people at high risk of developing diabetes. The International Society for Pharmaco-economic and Outcomes Research’s Questionnaire to Assess Relevance and Credibility of Modelling Studies for Informing Healthcare Decision Making was used to assess study quality.

Results 27 studies were included; all had evaluated lifestyle interventions and 12 also evaluated metformin. Primary studies exhibited considerable heterogeneity in definitions of pre-diabetes and intensity and duration of lifestyle programmes. Lifestyle programmes and metformin appeared to be cost effective in preventing diabetes in high-risk individuals (median incremental cost-effectiveness ratios of £7490/quality-adjusted life-year (QALY) and £8428/QALY, respectively) but economic estimates varied widely between studies. Intervention-only programmes were in general more cost effective than programmes that also included a screening component. The longer the period evaluated, the more cost-effective interventions appeared. In the few studies that evaluated other economic considerations, budget impact of prevention programmes was moderate (0.13%–0.2% of total healthcare budget), financial payoffs were delayed (by 9–14 years) and impact on incident cases of diabetes was limited (0.1%–1.6% reduction). There was insufficient evidence to answer the question of (1) whether lifestyle programmes are more cost effective than metformin or (2) whether low-intensity lifestyle interventions are more cost effective than the more intensive lifestyle programmes that were tested in trials.

Conclusions The economics of preventing diabetes are complex. There is some evidence that diabetes prevention programmes are cost effective, but the evidence base to date provides few clear answers regarding design of prevention programmes because of differences in denominator populations, definitions, interventions and modelling assumptions.

INTRODUCTION

Diabetes is a global health priority, with 415 million known adult cases worldwide, of which 91% are type 2 diabetes.1 Ageing of the population is predicted to drive substantial increases in prevalence (estimated to 642 million by 2040),2 with particularly rapid increases in low-and-middle-income countries.3 The burden of complications in diabetes is high, including heart disease, stroke, neuropathy, nephropathy and retinopathy.1 Type 2 diabetes develops as a result of genetic, environmental and behavioural factors, including sedentary lifestyle and energy-rich, nutrient-poor diet, both of which predispose to obesity.3 Diabetes takes a significant toll on health budgets around the world, accounting for 5%–20% of total healthcare expenditure.
### Table 1: Diagnosis of pre-diabetes

<table>
<thead>
<tr>
<th>Type of pre-diabetes</th>
<th>Description</th>
<th>Diagnostic test used</th>
<th>Criteria for diagnosis</th>
<th>Incidence of T2DM (per person-year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impaired glucose tolerance</td>
<td>High blood glucose 2 hours after a drink containing 75g of sugar (eg, Lucozade)</td>
<td>Oral glucose tolerance test</td>
<td>WHO: 2 hours postload glucose of 7–11.1 mmol/L</td>
<td>0.045</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADA: 2 hours postload glucose of 7–11.1 mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IEC: N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>WHO criteria: 0.047</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADA criteria: 0.037</td>
<td></td>
</tr>
<tr>
<td>Impaired fasting glucose</td>
<td>High blood glucose following a period of fasting</td>
<td>Fasting plasma glucose</td>
<td>HbA1c: 6.0%–6.4%</td>
<td>WHO criteria: 0.036</td>
</tr>
<tr>
<td>HbA1c ‘at risk’ range</td>
<td>Glycated haemoglobin which estimates blood glucose levels over the previous 2–3 months</td>
<td>HbA1c</td>
<td>5.7%–6.4%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6.0%–6.4%</td>
<td></td>
</tr>
<tr>
<td>Impaired glucose tolerance and impaired</td>
<td>As above</td>
<td>Fasting plasma glucose and oral glucose tolerance test</td>
<td>6.0–6.9 mmol/L</td>
<td>0.070</td>
</tr>
<tr>
<td>fasting glucose</td>
<td></td>
<td></td>
<td>2 hours postload glucose: 7–11.1 mmol/L and fasting plasma glucose: 7–11.1 mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5.6–6.9 mmol/L</td>
<td></td>
</tr>
</tbody>
</table>

ADA, American Diabetes Association; IEC, International Expert Committee; N/A, Not applicable; T2DM, Type 2 Diabetes Mellitus.
Programmes in these trials were intensive and sustained: 3–10 years of individual and group sessions provided by specialist staff (dieticians or exercise physiologists with annual physician review). Subsequent translation of these findings into large-scale community-based programmes produced interventions that were both shorter (3–12 months) and less intense (eg, they offered less sessions and were delivered to groups rather than individuals by non-specialist staff such as lay workers or prevention managers). These large-scale community-based programmes have been offered to populations of similar age and BMI to the large trials but with different selection criteria (eg, selection based on elements of the metabolic syndrome rather than the criteria of IGT seen in the large trials).19 There is some evidence that these pragmatic interventions offered to a real-world population deliver more limited and less sustained benefits than were seen with more intensive interventions in trial populations.20

Given the potential impact on populations and health budgets, the burden of type 2 diabetes is a key issue for policymakers. In response, a number of countries, including the USA and the UK, are developing (or seeking to develop) national diabetes prevention programmes.21 22 The design of large-scale prevention programmes incorporates a number of important choices: (1) whether to screen a portion of the population for diabetes risk or focus on people who are already known to have pre-diabetes; (2) if no screening programme is in place, how to identify participants who may benefit from a diabetes prevention programme; (3) the role of different types of interventions (lifestyle programmes or metformin) and (4) the optimum intensity and duration of the programme.

This study was designed to help inform decision-making by local and national policymakers and health insurers in countries with a high and/or rising incidence of type 2 diabetes. Our research question was:

1. What is the evidence on cost-effectiveness of lifestyle programmes or metformin in diabetes prevention?

2. What is the impact of the following factors on the cost-effectiveness of these interventions?

   a. Type of pre-diabetes (IFG, IGT or ‘at risk’ HbA1c).
   b. Intensity of lifestyle intervention: Including three different measures of intensity, each of which was examined separately: (i) frequency of contact in initial ‘core’ teaching/coaching sessions, (ii) duration of core and maintenance intervention and (iii) group or individual format of sessions.
   c. Inclusion of screening: Intervention-only studies on a predefined pre-diabetic or high-risk population or screening for pre-diabetes followed by intervention.
   d. Years of follow-up to evaluate diabetes incidence: <10 years and ≥25 years.

3. What are the implications of these findings for policymakers and health insurers?

A number of systematic reviews of economic evaluations of diet and exercise in diabetes prevention have been undertaken in the last 10 years.23–27 This paper is the first review to consider the cost-effectiveness of metformin and the first review to examine intervention-only and screening-plus-intervention studies separately. In addition, this paper adds to previous reviews by updating the data set with two new primary studies not included in previous systematic reviews28 29 and evaluating studies’ relevance for decision-making by policymakers and health insurers.

METHODS

Search strategy and inclusion criteria

A database search (covering Embase, PreMedline, Medline and NHS EED) for peer-reviewed articles on pre-diabetes and diabetes prevention between 2004 (the year before the publication of the first cost-effectiveness review of the USDPP) and 2014 identified 3833 papers. Search terms are outlined in online supplementary appendix 1. Citation tracking and screening of references (in included studies and review articles) identified a further 28 papers up to April 2016. Duplicates were removed and abstracts screened by two reviewers (EB, SR). We included studies that reported full economic evaluation (cost-effectiveness, cost-utility or cost-benefit analysis) of (1) lifestyle programmes, (2) metformin or (3) screening in combination with lifestyle programmes and/or metformin against a base case of usual care or no intervention.

To meet our inclusion criteria, economic evaluations needed to have

1. evaluated the treatment of pre-diabetes with either metformin and/or lifestyle programmes (that addressed diet and physical activity);
2. included ≥12 months of intervention and follow-up;
3. quantified outcomes (such as change in quality-adjusted life-years (QALYs), disability-adjusted life-years (DALYs), life-years gained (LYG) or numbers needed to treat to prevent one case of type 2 diabetes);
4. described the method used to classify people as high risk of developing type 2 diabetes (hence eligible for interventions), including: blood tests for pre-diabetes (any in table 1), screening questionnaires, diabetes risk algorithms or presence of particular risk factors.

Review articles were excluded as were articles focusing only on women with a history of gestational diabetes.

Full papers meeting the above criteria were reviewed; data were extracted from included papers (by SR) and data extraction for a third of papers was checked by a second reviewer (EB).

Quality assessment

A checklist developed by the International Society for Pharaco-economics and Outcomes Research (the ISPOR-AMCP-NCP questionnaire30) was used to evaluate the relevance and credibility of modelling studies for decision-making by policymakers.
Assumptions and calculations

All the economic evaluations included in this review were cost-effectiveness analyses (including cost-utility analyses), which measure both the cost of the intervention and the impact of the intervention on participants’ quality and/or length of life. No full cost-benefit analyses were identified. Cost-effectiveness analyses report their results as ratios of incremental costs divided by incremental benefits; in an incremental cost-effectiveness ratio (ICER). Resources to spend on healthcare are finite, so policymakers set a ‘willingness-to-pay’ threshold against which a treatment’s ICER is compared. Historically, the National Institute for Health and Care Excellence (NICE) in the UK has approved new technologies below the willingness-to-pay threshold of £20 000–£30 000/QALY, the USA has used a threshold of $50 000/QALY and WHO has recommended cost less than the per capita gross domestic product of the relevant country per DALY as the threshold. For this review, we used a willingness-to-pay threshold of £20 000/QALY. This means that if an intervention is below the willingness-to-pay threshold (costs <£20 000 per QALY), the intervention is considered cost effective. If the intervention costs more than the willingness-to-pay threshold, it is considered not cost effective. An intervention is only cost saving if it is more effective and costs less than current treatment.

Costs are reported in British pounds 2015 using purchasing power parity and currency exchange rates from the CCEMG-EPPi-Centre Cost Converter. Costs of lifestyle interventions were calculated in 2015 British pounds where sufficient data were available on constituent activities and staff involved, drawing on the Personal Social Services Research Unit for UK staff cost estimates.

ICERs are reported separately for each outcome measure: as either cost saving or £/QALY gained (£/QALY), £/DALY averted (£/DALY) or £/life-year gained (£/LYG) (box).

ICERs are reported from two different perspectives: health system and societal perspective. The health system perspective includes only direct medical costs such as (1) staff, facilities, medication and consumables costs required for provision of the intervention; and (2) general healthcare of participants. In addition, studies of cost-effectiveness from a societal perspective include some or all elements of (1) indirect costs of the intervention (eg, exercise equipment, food preparation equipment), (2) participant time (travelling to and participating in intervention’s activities), (3) lost productivity due to absence from work and (4) disability benefits payments.

Studies were grouped on a number of dimensions to identify key drivers of differences through subgroup analysis. Subgroups examined included: type of pre-diabetes, intensity of lifestyle intervention (defined by number of sessions in ‘core’ intervention, duration of core and maintenance programme, group vs individual format), inclusion of screening and years of follow-up to evaluate diabetes incidence. Subgroup medians could not be derived for the type of pre-diabetes as the majority of studies used IGT to identify eligible participants (with or without IFG), and there were two or less studies that reported £/QALY using each of the remaining methods of identification. Therefore, in order to understand the potential significance of the type of pre-diabetes we undertook a meta-analysis of randomised controlled trials of lifestyle programmes for diabetes prevention. Data were extracted from the 22 primary studies that reported diabetes incidence as an end point that were included in three recent systematic reviews of lifestyle programmes in diabetes prevention. Data were analysed in RevMan V.5.3. Due to the heterogeneity of the primary studies, we used a random-effects model and analysed subgroups defined by the trials’ inclusion criteria (IFG, IGT, HbA1c or risk score) and duration of the intervention. Forest plots were generated to illustrate the relative risk of diabetes following a lifestyle programme for each of these groups compared with no intervention.

Patient and public involvement

This review was conceptualised by a multidisciplinary group, including lay members, in Newham, East London. The authors attended regular project meetings of this group, reporting back the results of the review to the rest of the team.

RESULTS

In total, 42 full papers were reviewed and 15 were excluded for reasons outlined in figure 1.

In total, 27 studies of diabetes prevention programmes with economic evaluations have been published from 15 countries between 2004 and 2016. Six of the economic evaluations were within-trial cost-utility analyses and 21 were modelling studies (16 Markov models, 2 simulation models, 2 decision trees and 1 combination Markov model and decision tree). Within the modelling studies there were a wide range of model structures, parameters and parameter values which in part drive the variability observed in study results.
Type of intervention
All 27 studies evaluated lifestyle interventions and 12 also evaluated metformin (online supplementary appendix 2). Thirteen reported interventions in a population previously identified as pre-diabetic (people with IFG, IGT or high HbA1c) and 14 reported screening of a broader population and subsequent intervention on those identified as high risk of developing type 2 diabetes. The majority of studies evaluated intensive trial-based interventions, although there was a great deal of heterogeneity in the type of lifestyle interventions evaluated. Table 2 describes some of the dimensions on which lifestyle programmes differed: frequency of contact, duration, staff providing intervention, individual versus group interventions and frequency of contact.

Three studies did not specify the details of their lifestyle interventions.

Intensive trial-based lifestyle programmes
In total, 18 of the 24 studies that did describe in detail the lifestyle intervention being evaluated were based on intensive trial-based lifestyle interventions (8 based on the USDPP, 4 on the USDPP together with the US Diabetes Prevention Program Outcome Study, 3 on the Finnish Diabetes Prevention Study, 1 on the Da Qing study, 1 on the Indian Diabetes Prevention Programme and 1 on DE-PLAN-CAT). The primary studies were generously resourced, large (300–3000 participants) and provided lengthy interventions (3–10-year duration) including 7–16 initial contacts in the ‘core programme’ delivered by specialist staff (dieticians, exercise physiologists and annual medical review). Two within-trial studies reported intensive trial-based lifestyle programme costs in sufficient detail for costs to be reconstituted on an activity-based costing basis (online supplementary appendix 3). The costs in 2015 British pounds of these interventions were as follows: £2915 per participant over 3 years for the USDPP lifestyle programme, £4001 per participant over 3 years for the Indian DPP lifestyle programme (excluding staff travel costs).

Translational community-based programmes
In total, 3 of the 24 studies were based on community translation of these intensive interventions lasting 3–5 years and 3 studies were based on other published studies covering much smaller populations (<150 participants) and providing less intensive interventions (ranging from 12 weeks to 1 year in duration), delivered by non-specialist staff (diabetes prevention facilitators and lay workers).
<table>
<thead>
<tr>
<th>Clinical trial on which intervention is based</th>
<th>Included studies in this review</th>
<th>Number of sessions</th>
<th>Length of intervention</th>
<th>Staff delivering programme</th>
<th>Group or individual</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Diabetes Prevention Program (USDPP)</td>
<td>47, 48, 49, 50, 51, 28, 63, 58</td>
<td>16 core sessions, monthly follow-up</td>
<td>2.8 years</td>
<td>Exercise physiologists, dieticians, case managers</td>
<td>Predominantly individual</td>
</tr>
<tr>
<td>USDPP and Diabetes Prevention Program Outcomes Study</td>
<td>40, 57, 29, 61</td>
<td>Years 1–3: 16 core sessions, monthly follow-up Year 4: 16-session group programme Years 5–10: quarterly 1-hour group sessions, two additional ‘BOOST’ sessions per year for participants originally randomised to lifestyle group</td>
<td>10 years</td>
<td>Exercise physiologists, dieticians, case managers</td>
<td>Individual and group</td>
</tr>
<tr>
<td>Finnish DPS lifestyle programme</td>
<td>46</td>
<td>Year 1: seven visits Year 2 onwards: four visits per annum YMCA gym membership to enable two supervised exercise sessions per week</td>
<td>5 years</td>
<td>Dietician</td>
<td>Individual dietician visits, group exercise sessions</td>
</tr>
<tr>
<td></td>
<td>52</td>
<td>Year 1: seven visits Year 2 onwards: four visits per annum Supervised circuit-type training</td>
<td>6 years</td>
<td>Nutritionist</td>
<td>Individual visits, group exercise sessions</td>
</tr>
<tr>
<td></td>
<td>55</td>
<td>Weekly visits for 1 month, monthly for a further 3 months, quarterly thereafter</td>
<td>As long as participant has impaired glucose tolerance</td>
<td>Dietician, exercise physiologist</td>
<td>Individual</td>
</tr>
<tr>
<td>Indian Diabetes Prevention Programme</td>
<td>64</td>
<td>Individual sessions twice a year, monthly phone calls</td>
<td>3 years</td>
<td>Dieticians, social workers and helpers</td>
<td>Individual</td>
</tr>
<tr>
<td>Da Qing Lifestyle Program</td>
<td>62</td>
<td>Individual counselling by physicians or group counselling in nine sessions/year</td>
<td>6 years</td>
<td>Physicians</td>
<td>Individual and group</td>
</tr>
<tr>
<td>DE-PLAN-CAT/PREDICE</td>
<td>44</td>
<td>4×90 min teaching sessions Reinforced with telephone calls, text messages, letters and interviews every 6–8 weeks</td>
<td>4.2 years</td>
<td>Doctors and nurses</td>
<td>Individual or group</td>
</tr>
</tbody>
</table>

**Translational community-based lifestyle programmes**

Continued
<table>
<thead>
<tr>
<th>Clinical trial on which intervention is based</th>
<th>Included studies in this review</th>
<th>Number of sessions</th>
<th>Length of intervention</th>
<th>Staff delivering programme</th>
<th>Group or individual</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community-based translations of USDPP</td>
<td>60</td>
<td>16 core sessions in community setting, monthly follow-up</td>
<td>3 years</td>
<td>Diabetologists and dieticians</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>53</td>
<td>Nationwide programme</td>
<td>Year 1: 16 core sessions, postcore sessions every six months Year 2: eight maintenance sessions Year 3: 1–2 sessions</td>
<td>3 years</td>
<td>Lifestyle coaches in years 1 and 2, any healthcare provider thereafter</td>
</tr>
<tr>
<td></td>
<td>41</td>
<td>12 sessions</td>
<td>12–14-week intervention, 1-year follow-up</td>
<td>Health professionals, lay workers</td>
<td>Group</td>
</tr>
<tr>
<td>Hypothetical lifestyle programme</td>
<td>56</td>
<td>Eight core sessions Follow-up: quarterly sessions, monthly calls or emails, newsletter, quarterly journal</td>
<td>5 years</td>
<td>Prevention managers</td>
<td>Group</td>
</tr>
<tr>
<td>UEA-IFG</td>
<td>42</td>
<td>Four core education sessions and group exercise sessions Peer support groups Telephone peer support from volunteers</td>
<td>7 months</td>
<td>Physiotherapists, diabetes prevention facilitators, volunteers (people with T2DM for &gt;2 years)</td>
<td></td>
</tr>
<tr>
<td>Kalmar Metabolic Syndrome Program</td>
<td>43</td>
<td>NR</td>
<td>1 year</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

NR, Not reported; YMCA, The Young Men's Christian Association, a worldwide organisation providing local community services.
Target population: demographics and type of pre-diabetes

The target population for 16 of the 27 studies were overweight individuals with IGT, with or without IFG. Four used IFG alone,42 52 56 63 two used IGT or IFG,44 51 one used IFG or HbA1c,53 one used HbA1c alone,49 and three used other methods of screening (such as diabetes risk algorithms, BMI or other elements of metabolic syndrome).41 43 45 Also, 17 out of 27 studies included participants based on a BMI ≥ 24 kg/m², 3 included participants based on a BMI ≥ 30 mg/kg² and the remainder did not state a BMI cut-off for participation. A wide range of ages (from 18 years and older) were included.

Benefits of interventions

The primary benefit of diabetes prevention programmes is reduction in incidence of type 2 diabetes and its associated complications, measured in the number needed to treat to delay or prevent a case of diabetes or improvements in QALYs, DALYs and LYG, as summarised in online supplementary appendix 4.

Lifestyle interventions

In total, 21 studies reported change in QALYs associated with lifestyle interventions with a median 0.159 (range: 0.003-2.91) increase in QALYs and 13 reported LYG with a median increase of 0.30 (range: 0.04-0.84) increase relative to usual care. Four studies reported numbers needed to treat with lifestyle programmes to prevent one case of type 2 diabetes with results ranging from 4.2 to 30.

Metformin

Eight studies measured change in QALYs associated with metformin therapy with a median of 0.105 (range: 0.01-2.83) increase in QALYs and five studies reported increase in LYG with a median gain of 0.14 (range: 0.05-0.3). Two studies reported number needed to treat with metformin to prevent 1 case of type 2 diabetes as 6.9 and 27.9.

Side effects of screening or intervention

The impact of screening and intervention on length of quality of life was included as a change in incremental QALYs in a number of studies,49-51 and three studies modelled the impact of adverse effects explicitly.40 47 57

Value for money

Policymakers may consider a range of economic factors when considering a new programme: cost-effectiveness, budget impact, effect on incident cases of the disease and equity of healthcare provision.66 All studies included in this review considered cost-effectiveness, reporting ICERs, five described budget impact, two modelled impact on incident cases of diabetes and none considered impact on equity of healthcare provision.

Cost-effectiveness

Overall, lifestyle interventions and metformin appeared to be cost effective in preventing diabetes in high-risk individuals, as summarised in table 3, though there was wide variation in economic estimates between studies. Substantial differences in participant selection and intervention design, which reflect the different types of pre-diabetes and different types of interventions, as well as differences in model structure, parameters and parameter values, make comparison between studies difficult.

There is insufficient evidence to suggest that lifestyle interventions or metformin will be cost saving. Out of 27 studies, lifestyle interventions were found to be cost saving in 2 studies from a health system perspective,55 57 cost saving from a health system perspective in some countries but not others in one study20 and cost saving from a societal perspective in three studies.32 60 62 Of the 12 studies evaluating metformin, 2 studies concluded metformin was cost saving from a health system perspective,40 46 1 study concluded metformin was cost saving from a health system perspective in some countries but not others17 and 2 concluded metformin was cost saving from a societal perspective.40 61

Lifestyle programmes appear to be cost effective. Of the 16 studies measuring cost-effectiveness as £/QALY, the median ICER from a health system perspective was £7490/QALY (range: cost saving to £134 420/QALY). Only two studies reported lifestyle interventions that were not cost effective (costing >£20000 per QALY); of these, one used a model substantially different in structure to other modelling studies included (the Archimedes model, which analyses changes in biological variables, such as insulin resistance, rather than transitions between disease states, such as pre-diabetes, which are used by other models)16 and the other included analysis lasting only 1 year; therefore, the benefits of reduced incidence of diabetes were not included.52

Metformin also appears to be cost effective from a health system perspective. Of the seven studies measuring cost-effectiveness as £/QALY, the median ICER from a health system perspective was £8428/QALY (range: cost saving to £32 430/QALY). Two studies reported metformin to not be cost effective (costing >£20000 per QALY); of these, one used a model substantially different in structure to other modelling studies included (the Archimedes model)48 and the other was the first economic model of the USDPP.49 The subsequent models based on the USDPP and its follow-up study have found metformin to be cost saving or cost effective.40

Twelve studies compared lifestyle programmes and metformin directly. From a health system perspective, neither intervention appears more cost effective than the other with six studies reporting lifestyle programmes more cost effective than metformin,46 49 54 57 58 60 five studies,40 43 47 57 reporting metformin more cost effective than lifestyle programmes and one62 showing <1% difference in cost-effectiveness between the two. However, from a societal perspective, metformin appears more cost effective than lifestyle programmes, with four40 48 58 62 out of the five studies undertaking this analysis finding metformin more cost effective. This is because the cost of participants’ time travelling to and attending lifestyle programme sessions is included in most calculations of.
### Table 3 Incremental cost-effectiveness ratios (ICERs)

**ICERs: lifestyle intervention**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Duration of analysis</th>
<th>Range in base case</th>
<th>Mean ICER</th>
<th>Unit</th>
<th>Cost elements included in ICER from societal perspective</th>
<th>ICER in 2015 GBP</th>
<th>Range in base case</th>
<th>Mean ICER</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Lifetime</td>
<td></td>
<td>1057</td>
<td>£/QALY</td>
<td>Not specified</td>
<td>1057</td>
<td></td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>30 years</td>
<td>134 420</td>
<td>134 420</td>
<td>£/QALY</td>
<td>Participant time, food, food preparation and exercise equipment and classes</td>
<td>58 844</td>
<td>58 844</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Lifetime</td>
<td>7628</td>
<td>7628</td>
<td>£/QALY</td>
<td>Participant time, transport costs, fitness equipment, food costs and food preparation costs, days of work lost due to T2DM</td>
<td>10 917</td>
<td>10 917</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Lifetime</td>
<td>1210–1480</td>
<td>1345</td>
<td>£/QALY</td>
<td>Participant time, food, food preparation and exercise equipment and classes</td>
<td>58 844</td>
<td>58 844</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>3 years</td>
<td>12 544</td>
<td>12 544</td>
<td>£/QALY</td>
<td>Participant time, transport costs, fitness equipment, food costs and food preparation costs, days of work lost due to T2DM</td>
<td>26 764</td>
<td>26 764</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Lifetime</td>
<td></td>
<td></td>
<td></td>
<td>Participant time, travel and work absence</td>
<td>8709</td>
<td>8709</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Lifetime</td>
<td>7526–8750</td>
<td>8138</td>
<td>£/QALY</td>
<td>Not specified</td>
<td>15 037–17 275</td>
<td>16 156</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Lifetime</td>
<td>7526–8750</td>
<td>8138</td>
<td>£/QALY</td>
<td>Transport, lost income, cost of home care</td>
<td>Cost saving (−1190 to −2933)</td>
<td>Cost saving (−2062)</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>50 years</td>
<td>7490</td>
<td>7490</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>56</td>
<td>Lifetime</td>
<td></td>
<td></td>
<td></td>
<td>Participant transport</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>3 years</td>
<td>3215</td>
<td>3215</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>43</td>
<td>Simulation until 85 years of age</td>
<td>3140–17 802</td>
<td>10 471</td>
<td>£/QALY</td>
<td>Participant transport and non-healthcare organisations costs</td>
<td>Cost saving to £17 281</td>
<td>8641</td>
<td>£/QALY</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>70 years</td>
<td>3822–5390</td>
<td>4606</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>42</td>
<td>1 year</td>
<td>76 566</td>
<td>76 566</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>44</td>
<td>4 years</td>
<td>3275</td>
<td>3275</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>28</td>
<td>Lifetime</td>
<td>573</td>
<td>573</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>63</td>
<td>10 years</td>
<td>10 416</td>
<td>10 416</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>53</td>
<td>25 years</td>
<td>Cost saving (−6149)</td>
<td>Cost saving (−6149)</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
<tr>
<td>61</td>
<td>10 years</td>
<td>15 191</td>
<td>15 191</td>
<td>£/QALY</td>
<td>Participant transport</td>
<td></td>
<td>Cost saving (−15 259 to −31 721)</td>
<td>Cost saving (−23 490)</td>
<td>£/QALY</td>
</tr>
</tbody>
</table>

Continued
### Table 3: ICERs: lifestyle intervention

<table>
<thead>
<tr>
<th>Reference</th>
<th>Duration of analysis</th>
<th>Range (in base case)</th>
<th>Mean ICER</th>
<th>Unit</th>
<th>Cost elements included in ICER from societal perspective</th>
<th>Range (base case)</th>
<th>Mean ICER</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>Lifetime</td>
<td>Cost saving to 8614</td>
<td>1783</td>
<td>£/LYG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>10 years</td>
<td>577</td>
<td>577</td>
<td>£/LYG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Age 100 or death</td>
<td>15460</td>
<td>15460</td>
<td>£/DALY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>10 years</td>
<td>Not specified</td>
<td></td>
<td></td>
<td>Participant and healthcare professionals' time</td>
<td>23183</td>
<td>23183</td>
<td>£/DALY</td>
</tr>
<tr>
<td>60</td>
<td>3 years</td>
<td>4003</td>
<td>4003</td>
<td>£/case of T2DM avoided</td>
<td>Participant and healthcare professionals' time</td>
<td>23183</td>
<td>23183</td>
<td>£/DALY</td>
</tr>
</tbody>
</table>

### Table 3: ICERs: metformin

<table>
<thead>
<tr>
<th>Reference</th>
<th>Duration of analysis</th>
<th>Range (base case)</th>
<th>Mean</th>
<th>Unit</th>
<th>Range (base case)</th>
<th>Mean</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Lifetime</td>
<td>29409</td>
<td>29409</td>
<td>£/QALY</td>
<td>33392</td>
<td>33392</td>
<td>£/QALY</td>
</tr>
<tr>
<td>48</td>
<td>30 years</td>
<td>32430</td>
<td>32430</td>
<td>£/QALY</td>
<td>33392</td>
<td>33392</td>
<td>£/QALY</td>
</tr>
<tr>
<td>40</td>
<td>10 years</td>
<td>Cost saving</td>
<td>Cost saving</td>
<td>£/QALY</td>
<td>Cost saving</td>
<td>Cost saving</td>
<td>£/QALY</td>
</tr>
<tr>
<td>57</td>
<td>Lifetime</td>
<td>5477</td>
<td>5477</td>
<td>£/QALY</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
<tr>
<td>58</td>
<td>3 years</td>
<td>15371</td>
<td>15371</td>
<td>£/QALY</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
<tr>
<td>54</td>
<td>50 years</td>
<td>8428</td>
<td>8428</td>
<td>£/QALY</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
<tr>
<td>28</td>
<td>Lifetime</td>
<td>332</td>
<td>332</td>
<td>£/QALY</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
<tr>
<td>61</td>
<td>10 years</td>
<td>15339</td>
<td>15339</td>
<td>£/QALY</td>
<td>Cost saving</td>
<td>10 735</td>
<td>£/QALY</td>
</tr>
<tr>
<td>47</td>
<td>Lifetime simulation</td>
<td>7290</td>
<td>7290</td>
<td>£/LYG</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
<tr>
<td>46</td>
<td>10 years</td>
<td>Cost saving</td>
<td>Cost saving</td>
<td>£/LYG</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
<tr>
<td>55</td>
<td>Age 100 or death</td>
<td>14960</td>
<td>14960</td>
<td>£/DALY</td>
<td>4648</td>
<td>4648</td>
<td>£/QALY</td>
</tr>
</tbody>
</table>

Continued
ICERs: metformin

<table>
<thead>
<tr>
<th>Reference</th>
<th>Duration of analysis (years)</th>
<th>Range (base case)</th>
<th>Mean</th>
<th>Cost per T2DM avoided (base case)</th>
<th>Cost per T2DM avoided (base case) Mean</th>
<th>GBPS Societal perspective</th>
<th>GBPS Health system perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>16</td>
<td>16296</td>
<td>27281</td>
<td>27281</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference</th>
<th>Duration of analysis (years)</th>
<th>Range (base case)</th>
<th>Mean</th>
<th>Cost per T2DM avoided (base case)</th>
<th>Cost per T2DM avoided (base case) Mean</th>
<th>GBPS Societal perspective</th>
<th>GBPS Health system perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>16296</td>
<td>27281</td>
<td>27281</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference</th>
<th>Duration of analysis (years)</th>
<th>Range (base case)</th>
<th>Mean</th>
<th>Cost per T2DM avoided (base case)</th>
<th>Cost per T2DM avoided (base case) Mean</th>
<th>GBPS Societal perspective</th>
<th>GBPS Health system perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>60</td>
<td>16296</td>
<td>27281</td>
<td>27281</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DALY, disability-adjusted life-years; DPP, Diabetes Prevention Program; GBP, British pounds; LYG, life-years gained; QALY, quality-adjusted life-years; T2DM, Type 2 Diabetes Mellitus.

Cost from a societal perspective, but not from a health system perspective.

Given the range of screening and lifestyle interventions provided, and the range of cost-effectiveness ratios, studies which reported ICERs as £/QALY from a health system perspective were grouped on a number of dimensions to identify key drivers of differences. The analyses revealed that:

1. Screening plus intervention studies tended to be less cost effective than intervention-only studies on average, but both approaches were associated with a wide range of ICERs highlighting current uncertainties. Of the 10 studies that reported £/QALY from a health system perspective for intervention-only studies, the median ICER was £4606/QALY (range: cost saving to £134 420/QALY). And the median ICER for the eight screening-plus-intervention studies was £7814/QALY (range: £573–76 566/QALY).

2. In general, the longer the period evaluated the more cost effective the interventions appeared. Studies that measured cost-effectiveness over a period of ≥25 years appeared more cost effective (median ICER: £2976/QALY) than studies that measured cost-effectiveness over ≤10 years (median ICER: £10 416).

3. There was insufficient evidence to conclude whether lifestyle programmes with a duration of <2 years, 2–6 years or >6 years were more or less cost effective: Of the nine studies that included lifestyle programmes with a duration of >2 years and <6 years, the median ICER was £3275/QALY (range: cost saving to £134 420/QALY). Three studies included interventions <2 years duration with a wide variety of results (ICERs of £3215 [43], £10 471 [45] and £76 566 [44]). And three reported interventions of >6 years duration with a median ICER of £7628/QALY (range: cost saving to £15 191/QALY).

4. There was insufficient evidence to conclude whether higher frequency of contact during ‘core sessions’ was more or less cost effective: Of the 11 studies that included lifestyle programmes with ≥16 core sessions, the median ICER was £7628/QALY (range: cost saving to £134 420/QALY). Three studies reported £/QALYs for lifestyle programmes with <16 core sessions with widely varying results (ICERs of £3215 [43], £3275 [46] and £76 566 [44]).

5. There was insufficient evidence to conclude whether group or individual core sessions were more or less cost effective: Of the 11 studies that included the core component of the lifestyle programme delivered on an individual basis, the median ICER was £7628/QALY (range: cost saving to £134 420/QALY). Three studies included lifestyle programmes where the core component was delivered in groups with a wide range of results (ICERs of £6214 [55], £3215 [43], £3275 [46] and £76 566 [44]).

There were insufficient studies in each group to conduct cost-effectiveness subgroup analysis by type of pre-diabetes. However, our meta-analysis of intervention
trials suggests that this may be an important factor. Meta-analysis of intervention trials showed that lifestyle interventions ≥3 years duration for participants with IGT reduced the relative risk of developing diabetes by 45% (95% CI 28% to 57%). Lifestyle interventions lasting <3 years in participants with IGT showed a 26% (95% CI 0% to 45%) relative risk reduction. There were insufficient studies to divide participants identified by other diagnostic criteria by duration of intervention. But for all studies that identified participants by IFG alone, IFG or IGT and presence of risk factors, the relative risk of diabetes was reduced by 37% (95% CI 12% to 55%), 23% (95% CI 5% to 38%) and 11% (95% CI −0.2% to 22%), respectively. No
studies used HbA1c alone as the diagnostic criteria for selecting participants.

Other measures impacting the ‘value for money’ judgement
Cost-effectiveness analysis only measures cost and benefit of an intervention for an individual participant. Policymakers, who are responsible for overall health budgets and the health of the population as a whole, may consider other measures (such as budget impact, impact on equity and impact on incident cases of the disease) when evaluating the impact of an intervention. In terms of budget impact, three studies45 59 60 estimated the cost of implementing a national diabetes prevention programme to be between 0.13% and 0.2% of annual national health expenditure in the Netherlands, Germany and Australia. Two studies53 59 modelled annual expenditures for lifestyle programmes, showing that net savings only exceeded net expenditures 9–14 years after initiating the prevention programme.

Failure to attend screening, enrol in an intervention or comply with an intervention means that the number of cases of diabetes prevented is lower than might be anticipated when extrapolating from trials. As a result of these factors, as well as the partial and finite impact of interventions, two studies45 60 estimated that only 0.1%–1.6% of cases of diabetes would be prevented by a population-wide programme in the Netherlands, Germany and a region of Germany. As an example of how this population-wide impact is calculated, Icks60 calculated that 29% of incident cases of diabetes in 3 years would be due to people with pre-diabetes (defined as IGT in this study). Of this pre-diabetic population, 30% of people would attend the screening test (oral glucose tolerance test (OGTT)), 40% and 59% would participate in the lifestyle intervention and metformin, respectively. In total, 32% of these would develop diabetes in 3 years with no intervention and 9.3% and 28.8% would develop diabetes with lifestyle and metformin respectively which resulted in 0.2% of incident cases of diabetes being prevented by metformin and 0.8% by lifestyle programmes. These rates of attendance and enrolment are based on best estimates, a recent systematic review found significant variation in participation rates seen in studies of lifestyle programmes.67

Quality, relevance/applicability and credibility of existing economic evaluations for current healthcare decision-making
Evaluation of studies against ISPOR’s Questionnaire to Assess Relevance and Credibility of Modelling studies for Healthcare Decision Making30 (online supplementary appendix 5) raised a number of issues. The most important of these for policymakers are outlined below. No studies were excluded on the basis of this evaluation.

Relevance/applicability of included studies (table 4)
Given the variety of lifestyle programmes and range of different types of pre-diabetes, we examined the extent to which the included studies reflect national guidance in the UK88 89 and the USA,9 21 and the areas in which they differ.

Health system context
In total, 24 out of 27 studies were undertaken in high-income, predominantly Caucasian nations. Only two studies62 64 were undertaken in developing countries, China and India.

Target population
Only 62 42 32 33 56 63 out of 27 studies used diagnostic tests for pre-diabetes that are in line with current UK guidance, that is, HbA1c or fasting plasma glucose. The majority of studies, 16 out of 27, included participants with a positive oral glucose tolerance test (with or without fasting blood glucose). Prevalence differs between different types of pre-diabetes, with the potential to have a large impact on budgets. For example, one study in this review61 compared the cost-effectiveness of different diagnostic tests and found that expanding the definition of pre-diabetes from IGT and IFG to IGT or IGT increased the number of eligible participants threefold, with the savings from reduced diabetes incidence insufficient to offset the increase in cost, with a resulting small reduction in cost-effectiveness.

Type of intervention
In total, 21 of the 27 studies evaluated intensive trial-based interventions or intensive translations of trial interventions, which reflect current ADA guidance (lifestyle interventions modelled on the USDPP, targeting 7% wt loss).9 However, reviews of community translations of the USDPP trial showed that while these translational programmes cost less to implement they were also less effective.19 20 The modelling studies based on the USDPP trial data may therefore not be relevant comparators for a USDPP-based community programme. In contrast, NICE in the UK and the Community Preventative Services Task Force in the USA advocate a more pragmatic approach to lifestyle programmes. Only three studies41–43 in this review are relevant comparators in terms of duration and intensity of lifestyle intervention and they report a wide range of cost-effectiveness (from £3215/QALY to £76 566/QALY). One study42 (ICER £76 566) was an in-trial cost-utility analysis over 1 year, therefore was unable to quantify the impact of the prevention programme on diabetes incidence. And one41 assumed treatment effects equivalent to those seen in a trial of an intensive lifestyle programme.

Credibility of included studies
Two key issues emerged with the assessment of the credibility of the modelling studies included in this review: (1) areas where updated evidence is available that may impact the evaluation and (2) areas where uncertainty persists and a range of assumptions are observed.

Availability of updated meta-analyses
In total, 12 of the 21 modelling studies assumed reductions in diabetes incidence equivalent to that achieved in the USDPP or Finnish Diabetes Prevention Study trials (relative risks of 0.50 at 3 years and 0.40 at 6 years respectively). However, two recent meta-analyses of randomised controlled trials37 38 have shown a relative risk of diabetes
Table 4  Relevance of included studies (numbers refer to the number of studies in this review in each category)

<table>
<thead>
<tr>
<th>Health system context</th>
<th>USA</th>
<th>UK</th>
<th>Europe</th>
<th>Australia</th>
<th>Canada</th>
<th>Singapore</th>
<th>India</th>
<th>China</th>
</tr>
</thead>
<tbody>
<tr>
<td>Which health system?</td>
<td>9</td>
<td>3</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target population</th>
<th>IGT (± IFG)</th>
<th>IFG</th>
<th>IFG or IGT</th>
<th>HbA1c</th>
<th>Other (eg, risk score)</th>
<th>Current guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Which diagnostic test for pre-diabetes?</td>
<td>16</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>UK: IFG or HbA1c for diagnosis ADA: IFG, IGT or HbA1c for diagnosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of intervention/s evaluated</th>
<th>Trial-based lifestyle programme</th>
<th>Pragmatic lifestyle programme</th>
<th>Not stated</th>
<th>Current guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial-based lifestyle or pragmatic lifestyle?</td>
<td>18 trial based</td>
<td>3 translations of trials</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
Sources: ADA: Standards of Medical Care in Diabetes,9 UK: NICE guidance,88 USA: Community Preventative Services Task Force recommendations.21
Some studies may be included in more than one category, for example, if the study took place across multiple countries or used multiple diagnostic tests.

Of 0.59 and 0.64. And a meta-analysis of pragmatic lifestyle interventions38 excluding large trials showed a relative risk of 0.74. The higher the relative risk, the less the effect of the intervention; therefore, these recent meta-analyses suggest that models based on DPP or DPS trial data will overstate the impact of interventions.

Key uncertainties regarding modelling assumptions
First, uncertainty remains over the extent to which the reduction in diabetes incidence persists once the intervention has ended. Studies included in this review made a wide range of assumptions on this point, ranging from no effect after the intervention ended to effects persisting until the participant developed type 2 diabetes or died. One recent meta-analysis37 showed relative risks of 0.80 at up to 20 years follow-up. However, this analysis includes predominantly the large trials (USDPP, Finnish DPS lifestyle programme and Da Qing) as long-term follow-up data are not available on community-based translational studies. Therefore, this relative risk likely overstates the long-term benefits of interventions outside the trial context. Second, uncertainty persists over the percentage of people that fail to enrol in lifestyle interventions following screening. Reflecting this uncertainty, five studies included in this review assumed 100% enrolment, two assumed between 50% and 99% and five assumed <50% enrolment. A recent systematic review87 found that enrolment in interventions varies widely (from 0.28% to 100%) depending on method of communication, setting and type of intervention. Finally, based on included studies, the relationship between the type of pre-diabetes and cost-effectiveness of the study is unclear. A factor which may be important given the differences in relative risk reductions illustrated by our meta-analysis.

DISCUSSION
Principal findings
This systematic review of economic evaluations of diabetes prevention programmes has produced seven major findings. First, that numerous economic evaluations have been undertaken in 15 different countries and produced diverse results due to differences in model structure and
parameter values and to differences in health systems, types of pre-diabetes and types of lifestyle interventions included. Second, that the majority of evaluations relate to intensive trial-based interventions in populations in high-income countries identified with the oral glucose tolerance test. Third, that with these caveats in mind, both metformin and lifestyle interventions in people with pre-diabetes appear to be cost effective but not cost saving despite their impact on reducing diabetes incidence, with median ICERS of £8428/QALY and £7490/QALY, respectively. To place this figure in context, smoking cessation services are estimated by NICE to have ICERS ranging from cost saving to £984/QALY and breast cancer screening is estimated to have an ICER of £20800/QALY by the UK Panel on Breast Cancer Screening.

The fact that diabetes prevention programmes are not cost saving is not due solely to the issue of discounting, as three studies report undiscounted cost-effectiveness ratios with only one of those appearing cost saving. Fourth, that metformin and lifestyle programmes appear equally cost effective when only the costs of the health system are taken into account, but metformin is more cost effective when costs of participants’ time (participating in and travelling to programme activities) are taken into account. Fifth, screening-plus-intervention programmes were less cost effective on average than intervention-only programmes. But both approaches were associated with a wide range of cost-effectiveness ratios and the population benefit of screening in identifying people with previously undiagnosed pre-diabetes is not taken into account, but metformin is more cost effective when costs of participants’ time (participating in and travelling to programme activities) are taken into account. Sixth, there is insufficient evidence to deduce what intensity, duration or format or lifestyle programmes are more cost effective than others. Finally, programmes that evaluated costs and benefits over ≥25 years were more cost effective than those that looked at ≤10 years.

Implications for policymakers

Both the type of pre-diabetes and the type of lifestyle programme have a substantial impact on the number of cases of diabetes that are delayed or prevented. Guidance in the UK and the USA advocate lower-intensity ‘pragmatic’ lifestyle programmes and there is a small amount of evidence that these are cost effective. In light of recent meta-analyses, historical studies are likely overstating treatment effects and uncertainty over duration of impact limits accurate long-term modelling. Guidance in the UK advocates the use of fasting plasma glucose or HbA1c in identifying people with pre-diabetes. There is currently insufficient data to conclude that interventions in people identified solely with HbA1c are cost effective, and no randomised controlled trials with HbA1c as the inclusion criteria to enable estimation of treatment effects. There is insufficient evidence to suggest that metformin is more cost effective than lifestyle programmes.

Policymakers need to make decisions even when all the evidence is not available, as is the case with the English national diabetes prevention programme (Healthier You: The NHS DPP) which provides low-intensity lifestyle programmes to people with IFG and or high HbA1c. In this case, rigorous evaluation alongside policy implementation could add to the evidence base, examining (1) what reduction in relative risk is associated with a large-scale implementation of a low-intensity lifestyle programme? (2) how does this reduction in risk attenuate over time? (3) how does reduction in relative risk differ by type of pre-diabetes?

In addition to these considerations of cost-effectiveness, policymakers may need to balance impact on health budgets, incident cases of diabetes and equity of healthcare provision. In the few studies where these were modelled, budget impact was moderate (prevention programmes required 0.13%–0.2% of respective countries total healthcare budget), financial payoffs were delayed (net expenditure on treatment and prevention of diabetes only declined after 9–14 years) and impact on incident cases of diabetes was limited (0.1%–1.6% reduction in incident cases). This suggests that other avenues to reducing incident cases of diabetes will need to be explored if substantial inroads are to be made in controlling the diabetes ‘epidemic’. These may include population-wide measures to address obesity, a primary determinant of progression to type 2 diabetes in a person with pre-diabetes.

Comparison with previous systematic reviews

Our findings confirm those of previous systematic reviews which have shown that lifestyle interventions are generally cost effective, but with a wide range of cost-effectiveness ratios, reflecting heterogeneity of interventions, target populations and modelling approaches. They have shown that lifestyle interventions appear more cost effective if group, rather than individual sessions, are provided and a long time horizon is adopted for analysis. They have raised the issue of the limited number of studies in low-income and middle-income countries, the concern that real-life implementation of programmes will be less effective than trial-based interventions, and the uncertainty that persists regarding long-term efficacy of these interventions. This review has added to previous work in three key areas: evaluation of metformin, comparison of screening-plus-intervention against intervention-only studies and consideration of the relevance and credibility of studies for decision makers.

Suggestions for further research

This study has identified three areas where further research would be beneficial. First, developing an understanding of how people with different types of pre-diabetes respond to interventions and the subsequent cost-effectiveness profiles for different diagnostic-treatment combinations. This could be undertaken in both modelling studies, using recent evidence from meta-analyses, or retrospective analysis of existing trial data where different types of pre-diabetes may coexist (eg, IGT and HbA1c, IGT and IFG or IGT-only participants). Second, long-term follow-up studies of pragmatic lifestyle intervention programmes are important to understand the duration of impact on diabetes incidence following cessation of the intervention; uncertainty in this
area limits the accuracy of long-term modelling studies. Finally, consideration of the role of broader social and environmental programmes (eg, sugar tax, increasing active travel) on diabetes incidence will be important as, based on studies in this review, individual lifestyle programmes and metformin are unlikely to be sufficient to address the vast majority of incident cases of diabetes.

CONCLUSIONS

National diabetes prevention guidance in the UK and USA advocates pragmatic lifestyle programmes (<3 years in duration), and in the UK the use of HbA1c or fasting plasma glucose is recommended for diagnosing pre-diabetes. However, the majority of cost-effectiveness studies relate to a different definition of pre-diabetes and a higher intensity of intervention, which limits the direct applicability of findings. In the few studies that evaluated other economic considerations, budget impact of prevention programmes was moderate, financial payoffs were delayed and impact on incident cases of diabetes was limited. There remains a need for long-term economic evaluation of programmes that reflect current policy and consideration of the role of broader social and environmental programmes on diabetes incidence.

Acknowledgements

The authors thank Newham Clinical Commissioning Group and University College Partners for their support of this project.

Contributors

SR and EB conceptualised the paper. SR led the data extraction and analysis and drafted the paper. EB and SR undertook the searches. MA, GB and DC were all advisers, and TS was the principal supervisor, on the DPhil of which our work is part. Risk models were developed by JB, EM, SR and EB, and EB undertook the meta-analysis. JB undertook the statistical analyses. TS was involved in the development of the diabetes prevention guidance in the UK and USA as well as the economic evaluation. ET and EB led the search strategy. RM was the principal supervisor, on the DPhil of which our work is part.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data available.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


